TargetMol

Topixantrone

Product Code:
 
TAR-T28994
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28994-5mg5mg£790.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28994-50mg50mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28994-100mg100mg£2,319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Topixantrone, a DNA topoisomerase inhibitor, is used potentially for the treatment of gastric cancer and prostate cancer.
CAS:
156090-18-5
Formula:
C21H26N6O2
Molecular Weight:
394.479
Purity:
0.98
SMILES:
CN(C)CCNc1ccc2n(CCNCCO)nc3-c4cnccc4C(=O)c1c23

References

1. Marini A, Berbenni V, Bruni G, Cofrancesco P, Margheritis C, Orlandi A, Villa M. Hydration, stability, and phase transformations of a new antitumor drug. J Pharm Sci. 2004 Sep;93(9):2222-31. PubMed PMID: 15295783. 2. Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer Drugs. 2004 Jan;15(1):15-22. PubMed PMID: 15090738.